What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Rheumatoid Arthritis Clinical Trials 2026: New Biologics, JAK Inhibitors & Remission

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Rheumatoid arthritis affects approximately 1% of the global population and remains a major cause of disability despite effective treatments. In 2026, clinical trials are focused on three goals: achieving drug-free remission (stopping treatment without disease flare), treating patients who fail multiple biologics and JAK inhibitors (refractory RA), and developing safer alternatives to current therapies with better cardiovascular and infection profiles.

Current Treatment Landscape and Where Trials Fit

Standard RA treatment progresses from methotrexate to biologics (TNF inhibitors, IL-6 inhibitors, abatacept, rituximab) to JAK inhibitors when biologics fail. Despite this, approximately 30–40% of patients don't achieve adequate disease control, and virtually all patients flare when treatment is stopped. Trials are addressing these gaps.

TYK2 Inhibitors: The New Option

Deucravacitinib (Sotyktu), a TYK2 inhibitor, was approved for psoriasis in 2022 and is now in Phase 3 trials for RA. TYK2 inhibitors have a more selective mechanism than pan-JAK inhibitors, potentially offering efficacy without the cardiovascular and thrombotic risks associated with JAK1/2/3 inhibition. The POETYK RA trials are actively recruiting patients who have failed at least one biologic.

CAR-T Cell Therapy for Refractory RA

The most striking development in RA research comes from a German group (Erlangen) that treated five patients with severe refractory RA using CD19-directed CAR-T cells — the same technology used in leukemia. All five achieved drug-free remission at follow-up. This represents a potential functional cure for a subset of patients. Phase 1/2 trials are now expanding this approach, recruiting patients who have failed multiple biologics and JAK inhibitors.

Eligibility typically requires: failure of ≥2 biologics with different mechanisms of action, failure of ≥1 JAK inhibitor, active disease (DAS28 >3.2), no prior malignancy, adequate organ function.

Drug-Free Remission Trials

Several trials are investigating whether patients in stable remission can safely taper and stop DMARDs. The ARCTIC REWIND and TARA trials have shown that a proportion of patients in sustained remission can stop TNF inhibitors without flare. New trials are identifying biomarkers (ACPA levels, ultrasound synovitis scores, gene expression profiles) that predict who can successfully stop treatment.

Who Can Join an RA Trial

Common eligibility requirements include: confirmed RA diagnosis (ACR/EULAR 2010 criteria), active disease at screening (swollen and tender joint counts, elevated CRP or ESR), specific treatment history requirements (e.g., failed methotrexate, failed ≥1 biologic), and washout periods from current medications. Pregnancy and active serious infection are standard exclusions. Many RA trials are sponsored by large pharmaceutical companies and conducted at rheumatology centers globally.